Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
收藏数据链接：
官方服务：
资源简介：
Supplementary Table S3: Targeted Sequencing Panel. List of regions included in the CHARM+EVOLVE panel used for targeted sequencing; coordinates are for human reference hg38.
创建时间：
2023-09-15
